CD8A and neoplasm: The percentage of CD8+ T cells (41.0%) in tumors from mice receiving mt-NPBodipy + L treatment was 1.5 times greater compared to those treated with NPBodipy (26.8%) and mt-NPBodipy (27.3%), indicating that mt-NPBodipy + L not only activated T cells but also increased the infiltration of CD8+ T cells within the tumor.